This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous s…

Diffuse Midline Glioma, H3 K27-AlteredMetastatic Malignant Neoplasm in the Central Nervous SystemRecurrent Diffuse Intrinsic Pontine Glioma+7 more

~Estimated

~$10 – $7,500

Children's Oncology GroupNCT04870944

Phase 1

LU-TARGET: A Phase 1 Study of Lutetium-177-PSMA-617 Adjuvant Radiotherapy for IDH Wild Type Gliomas Expressing PSMA Following Standard Treatment

The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type…

GliomaDiffuse Astrocytoma, IDH-Wildtype (Grade 2-4)Glioblastoma, IDH-wildtype+3 more

~Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07223034